(2S,4R)-1-((S)-17-Amino-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

Background Introduction

(2S,4R)-1-((S)-17-Amino-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide is a highly specialized small molecule designed for targeted protein degradation research. As a novel E3 ligase ligand-linker conjugate, this compound plays a vital role in the development of Proteolysis Targeting Chimeras (PROTACs) for chemical biology and drug discovery. Its unique structure allows seamless integration with a variety of target binding ligands, making it a versatile tool in the field of targeted protein degradation.

Mechanism

This E3 ligase ligand-linker conjugate works by selectively recruiting an E3 ubiquitin ligase to a protein of interest when tethered to a target binding moiety. The ligand portion specifically binds an E3 ligase, while the attached linker provides chemical flexibility and distance optimization for subsequent PROTAC assembly. When incorporated into a bifunctional PROTAC molecule, this conjugate brings the E3 ligase in close proximity to the target protein, facilitating ubiquitination and subsequent proteasomal degradation. This mechanism effectively removes disease-relevant proteins from cells in a highly selective manner.

Applications

(2S,4R)-1-((S)-17-Amino-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide is widely used in the synthesis of customized PROTACs for target validation, mechanism-of-action studies, and preclinical drug discovery. Researchers employ this conjugate to expand the toolbox for targeted protein degradation by designing new PROTACs with improved cell permeability and selectivity. It is an essential building block for developing novel therapeutic strategies against cancer, neurodegenerative diseases, and other pathologies where traditional inhibitors fall short.

The E3 Ligase Ligand-Linker Conjugate, (2S,4R)-1-((S)-17-Amino-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, is a crucial component in the design of PROTACs, facilitating targeted protein degradation. The following provides a detailed description of this molecule, including its linker, ligand, and reactive site characteristics.

Linker: The linker in this molecule is characterized by its moderate length and flexible nature, consisting of a polyether chain that enhances solubility and permeability. Its flexibility allows for optimal spatial orientation between the ligand and the target protein. The linker is non-cleavable, ensuring stability in cellular environments.

Ligand: This molecule features a ligand composed of a pyrrolidine carboxamide moiety conjugated with a thiazole-containing aromatic system. The ligand's structural characteristics confer high specificity and binding affinity to the E3 ligase, facilitating effective ubiquitination of target proteins.

Reactive Site: The reactive site is situated at the terminal amino group of the linker, which couples with the target protein ligand. Recommended reaction types include amide bond formation or click chemistry, allowing for versatile conjugation strategies with various warheads.

Recommended Target Protein Ligand: The compatible warhead for this molecule is one that features an electrophilic moiety, such as an acrylamide or chloroacetamide, enabling covalent bonding with cysteine residues on the target protein. This approach offers enhanced selectivity and irreversible inhibition, making it suitable for applications in studying protein function and degradation pathways.